Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

John Devin PeipertAustin G KulasekararajAnna GayaSaskia M C LangemeijerSusan YountF Ataulfo Gonzalez-FernandezEmilio Ojeda GutierrezChrista MartensAmy SparlingKimberly A WebsterDavid CellaIoannis TomazosMasayo OgawaCaroline I PiatekRichard WellsFlore Sicre de FontbruneAlexander RöthLindsay MitchellAnita HillKaren Kaiser

Published in: PloS one (2020)

This study shows that a substantial proportion of patients preferred ravulizumab over eculizumab and provides an important patient perspective on PNH treatment when there is more than one treatment option.

Keyphrases

case report
blood pressure
end stage renal disease
combination therapy
physical activity
decision making
sleep quality
catheter ablation